US20080118444A1 - Lactobacillus paracasei-containing product - Google Patents
Lactobacillus paracasei-containing product Download PDFInfo
- Publication number
- US20080118444A1 US20080118444A1 US11/637,711 US63771106A US2008118444A1 US 20080118444 A1 US20080118444 A1 US 20080118444A1 US 63771106 A US63771106 A US 63771106A US 2008118444 A1 US2008118444 A1 US 2008118444A1
- Authority
- US
- United States
- Prior art keywords
- lactobacillus paracasei
- lactobacillus
- product
- containing product
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 98
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 41
- 241000894006 Bacteria Species 0.000 claims abstract description 24
- 208000014151 Stomatognathic disease Diseases 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 235000013351 cheese Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 235000021056 liquid food Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 235000021055 solid food Nutrition 0.000 claims description 3
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 235000011962 puddings Nutrition 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- 229940034610 toothpaste Drugs 0.000 claims 1
- 208000002925 dental caries Diseases 0.000 abstract description 56
- 244000052769 pathogen Species 0.000 abstract description 56
- 208000028169 periodontal disease Diseases 0.000 abstract description 32
- 210000000214 mouth Anatomy 0.000 abstract description 15
- 241000186660 Lactobacillus Species 0.000 description 27
- 229940039696 lactobacillus Drugs 0.000 description 24
- 241000193987 Streptococcus sobrinus Species 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- 230000001717 pathogenic effect Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 241000194019 Streptococcus mutans Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 208000002064 Dental Plaque Diseases 0.000 description 10
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000012453 sprague-dawley rat model Methods 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 241000605862 Porphyromonas gingivalis Species 0.000 description 5
- 241001135221 Prevotella intermedia Species 0.000 description 5
- 235000013024 sodium fluoride Nutrition 0.000 description 5
- 239000011775 sodium fluoride Substances 0.000 description 5
- 241001633684 Centipeda periodontii Species 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 208000018035 Dental disease Diseases 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100023991 E3 ubiquitin-protein ligase DTX3L Human genes 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101000904542 Homo sapiens E3 ubiquitin-protein ligase DTX3L Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000862991 Leptothrix <Bacteria> Species 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010072574 Periodontal inflammation Diseases 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
Definitions
- the present invention relates to a product used in oral cavity, and more particularly, to a Lactobacillus paracasei -containing product used for inhibiting dental diseases caused by bacteria.
- a dental caries is one of multi-factorial diseases caused by the following factors, including constituted element of teeth, configuration, position, component of saliva, pH value, secretion, viscosity, anti-bacterial factors, carbohydrate level in diet, fluoride, and microorganisms and their physical properties. Therefore, reducing the number of bacteria in oral cavity may reduce the occurrence of periodontal diseases caused by dental caries and bacteria.
- the bacteria affecting the health care of teeth are all in the form of a dental plaque, which is a film-shaped substance adhered on a surface of teeth in the oral cavity, with the appearance being gradually changed from a transparent appearance into a white deposit.
- the bacteria in the dental plaque include a variety of cocci, bacilli, and leptothrix, wherein the main bacteria of dental plaques that most easily causes dental caries or a periodontal inflammation include Streptococcus mutans, Streptococcus sanguis, Actinomyces viscosus, Streptococcus sobrinus , and Porphyromonas gingivalis.
- lactobacillus cultures for inhibiting the formation of the dental plaque are disclosed in U.S. Pat. No. 6,036,952, which include Enterococcus spp. 1357, Lactobacillus acidophilus V20, and Lactococcus lactis 1370.
- a product containing lactobacillus cultures of ATTC PTA-4965 and PTA-4964 is disclosed in U.S. Pat. No. 6,872,565, which is used for inhibiting dental caries caused by bacteria.
- the inhibition effect achieved by combining the ATTC PTA-4965 or PTA-4964 and an oral mucin or the dental plaque is used for effectively reducing the number of Streptococcus mutans .
- Lactobacillus paracasei may be used to promote an immunocyte to release a number of interferon, which is helpful for improving allergic diseases.
- Human immunocyte T lymphocytes are divided into two types according to the secreted different cytokines, wherein there is a dynamic balance between Type I and Type II T lymphocytes, and both of them are influenced by each other, thereby affecting the result of a reaction of the whole immune system to an antigen. If the reaction of Type II T lymphocyte is excessively strong, an allergic symptom occurs to a patient.
- the allergy may be prevented by increasing the activity of Type I T lymphocyte or inhibiting the activity of Type II T lymphocyte.
- the Lactobacillus paracasei When the Lactobacillus paracasei is used in human bowel, due to the difference of cell walls and cell contents, the Lactobacillus paracasei significantly promotes the activity of Type I T lymphocyte and further inhibits the effect of Type II T lymphocyte, and thus preventing allergy.
- lactobacilli are now found to have the function of inhibiting dental caries, dental plaques, and periodontal diseases.
- the Lactobacillus paracasei has been used in human bowel in the past to relieve the body allergic symptom after being absorbed by the bowel.
- the efficacy that the Lactobacillus paracasei is used in oral cavity to prevent dental diseases has not been found yet.
- the prevent invention provides a Lactobacillus paracasei -containing product, which is used for inhibiting dental diseases caused by bacteria, such as dental caries, dental plaques, and periodontal diseases.
- the Lactobacillus paracasei -containing product disclosed in the prevent invention is used for inhibiting dental diseases caused by bacteria, which comprises a plurality of Lactobacillus paracasei for inhibiting the growth of bacteria of dental diseases.
- Foods, oral hygiene products or oral treatment medicine containing the Lactobacillus paracasei when being administered or applied to a user can inhibit or reduce the number of pathogens of dental caries and periodontal diseases in oral cavity of the user, thereby achieving the efficacy of preventing dental diseases, such as dental caries and periodontal diseases.
- FIG. 1 is a DNA finger map of a Lactobacillus paracasei
- FIGS. 2A and 2B are results of an antimicrobial cycle test for inhibiting the pathogens of dental caries with the Lactobacillus paracasei;
- FIG. 3A is a result of an animal test in a control group
- FIG. 3B is a result of an animal test after inoculation of a pathogen S. sobrinus
- FIG. 3C is a result of an animal test for inhibiting the pathogen with a sodium fluoride after inoculation of the pathogen S. sobrinus;
- FIG. 3D is a result of an animal test for inhibiting the pathogen with the Lactobacillus paracasei at a low bacteria count after inoculation of the pathogen S. sobrinus;
- FIG. 3E is a result of an animal test for inhibiting the pathogen with the Lactobacillus paracasei at a high bacteria count after inoculation of the pathogen S. sobrinus;
- FIG. 4A shows a result for inhibiting the growth of pathogens of periodontal disease with an active Lactobacillus paracasei ;
- FIG. 4B shows a result for; inhibiting the growth of pathogens of periodontal disease with a sterilized Lactobacillus paracasei.
- a functional lactobacillus culture for alleviating dental disease symptoms is screened from the lactobacillus cultures existed in human bowel, which is a special lactobacillus culture for preventing dental caries screened from lactobacillus cultures in a culture collection center via the antimicrobial cycle test with the main pathogens Streptococcus mutans and Streptococcus sobrinus that cause the formation of dental caries.
- This functional lactobacillus culture is incubated in a culture dish without oxygen at a culture temperature of 37° C. for 16-24 hours. It is found in an experimental analysis that this lactobacillus culture is a Gram-positive bacteria, a non-sporing anaerobes, and a non-mobility, which is consistent with the property of the Lactobacillus paracasei.
- RAPD-PCR random amplified polymorphic DNA-polymerase chain reaction
- nucleotide sequencing is carried out for the lactobacillus culture with PAF and 536R primers.
- the sequencing result is compared with a gene database (the website is www.ncbi.nlm.nih.gov), and then, it is confirmed that this lactobacillus culture is the Lactobacillus paracasei .
- a part of the nucleotide sequencing result of the lactobacillus culture is shown as follows:
- the carbohydrate metabolism performance of the lactobacillus culture is tested with an API 50 CHL reagent.
- the API 50 CHL reagent is used for identifying the difference of cultures in genus or species. It is determined by analyzing the result that, the activity of carbohydrate metabolism of the lactobacillus culture is the same as that of the Lactobacillus paracasei (not shown in data).
- the screened special lactobacillus culture for preventing dental diseases is determined to be the Lactobacillus paracasei after being identified by the above analysis result.
- An antimicrobial cycle test for inhibiting the pathogen of dental caries is carried out after being modified according to the method of the National Committee for Clinical Laboratory Standards (NCCLS).
- NCLS National Committee for Clinical Laboratory Standards
- a platinum loop of pathogens of dental caries is inoculated in a desired culture medium.
- the strain is incubated at 37° C. for 18 hours to reach a log-growth phase.
- the bacteria count is measured with a Smart SpecTM 3000 Spectrophtometer, and the count of pathogens of dental caries is adjusted to 1.5 ⁇ 10 8 CFU/mL.
- the Streptococcus mutans and Streptococcus sobrinus are uniformly applied on the desired culture medium with a thickness of 4 mm, which is stand for 15 minutes, such that the coated bacteria solution is completely adhered on the culture medium.
- An asepsis filter paper disc with a diameter of 6 mm is used to soak and receive the solution of the Lactobacillus paracasei .
- the asepsis filter paper disc is gently pressed to be completely adhered on the culture medium that is uniformly coated with the Streptococcus mutans and Streptococcus sobrinus .
- the size of the antimicrobial cycle is judged and read after incubation at 37° C. for 72 hours.
- FIGS. 2A and 2B are results of the antimicrobial cycle test for inhibiting the pathogens of dental caries. After the Lactobacillus paracasei and the pathogens of dental caries were incubated together at 37° C. for 72 hours, the size of the antimicrobial cycle of the main pathogens Streptococcus mutans ( S. mutans ) and Streptococcus sobrinus ( S. sobrinus ) that cause dental caries is judged and read.
- S. mutans main pathogens Streptococcus mutans
- S. sobrinus Streptococcus sobrinus
- the result of the test shows that, the antimicrobial cycle caused by the Lactobacillus paracasei for the two trains of pathogens is larger than that of a Lactobacillus rhamnosus GG, i.e., the competitive antagonize effect of the Lactobacillus paracasei for the Streptococcus mutans and Streptococcus sobrinus is more preferable than that of the Lactobacillus rhamnosus GG.
- the Lactobacillus rhamnosus GG is a lactobacillus culture now widely used in healthy foods for reducing the occurrence of dental caries. Therefore, using the Lactobacillus paracasei in oral cavity is helpful for reducing the number of the Streptococcus mutans , the occurrence of dental caries, and the occurrence of the periodontal diseases caused by dental caries and bacteria.
- mice Female pregnant Sprague-Dawley (SD) mice are bought from the National Laboratory Animal Center. When infant mice are 18 days old, a 0.2 ml culture solution incubated overnight for the pathogen S. sobrinus of dental caries at a log-growth phase is touched with a cotton stick, and then, the culture solution is applied in the oral cavity of female mice for inocuability. A 10% aqueous sucrose solution is available for the female mice without limitation. The step of inocuability is repeated at the second day. The caries bacteria S.
- sobrinus is applied in the oral cavity of the female mice with a sterile cotton stick at the third day of inocuability; and then, it is incubated in a Mitis Salivarius culture medium containing 100 ⁇ g/ml Streptomycin ; finally, it is inspected whether the inocuability is successful.
- the SD infant mice are ablactated on the 20 th day, and then, they are divided into groups.
- a 0.2 ml culture solution incubated overnight for the pathogen S. sobrinus of dental caries at a log-growth phase is touched with a cotton stick, and then, the culture solution is applied in the oral cavity of SD infant mice for inocuability.
- a 10% aqueous sucrose solution is available for the SD infant mice without limitation.
- the step of inocuability is repeated at the second day.
- sobrinus is applied in the oral cavity of the SD infant mice with a sterile cotton stick at the third day of inocuability; and then, it is incubated in a Mitis Salivarius culture medium containing 100 ⁇ g/ml Streptomycin ; finally, it is inspected whether the inocuability is successful.
- the aqueous sucrose solution is available for the SD infant mice without limitation during the period from the 23 rd day since the mice were born to the completion of the test. Body weights are measured before the efficacy test, and the body weights are measured once a week during the test. The SD infant mice are sacrificed after 5 weeks for observing the degree of dental caries.
- FIGS. 3A-3E show results of the animal test for inhibiting the pathogens of dental caries.
- FIG. 3A is a test result of a bank group. The pathogens of dental caries are not incubated, and the aqueous sucrose solution added with the Lactobacillus paracasei is not available throughout the test.
- FIG. 3B is a test result of the inoculation of a pathogen S. sobrinus .
- FIG. 3C is a test result for using an aqueous sucrose solution containing 0.022% NaF after inoculation of the pathogen S. sobrinus .
- FIG. 3A is a test result of a bank group. The pathogens of dental caries are not incubated, and the aqueous sucrose solution added with the Lactobacillus paracasei is not available throughout the test.
- FIG. 3B is a test result of the inoculation of a pathogen S. sobrinus .
- FIG. 3C is
- FIG. 3D is a test result for using an aqueous sucrose solution containing 5 ⁇ 10 9 CFU/ml Lactobacillus paracasei after inoculation of the pathogen S. sobrinus .
- FIG. 3E is a test result for using an aqueous sucrose solution containing 5 ⁇ 10 11 CFU/ml Lactobacillus paracasei after inoculation of the pathogen S. sobrinus.
- the test conditions in FIG. 3C include that the aqueous sucrose solution containing 0.022% NaF is available for the mice from the 23 rd day after the inoculation for the pathogen S. sobrinus of dental caries is successful; the pH value of the aqueous solution is 7; the concentration of Fluoride ion is 100 ppm.
- the test conditions in FIGS. 3D and 3E include that the Lactobacillus paracasei at the bacteria count of 5 ⁇ 10 9 CFU/ml and 5 ⁇ 10 11 CFU/ml are respectively fed to the mice at 23 days after the inoculation for the pathogen S. sobrinus of dental caries is successful. Each SD mouse is fed with 0.05 ml on left and right cheek respectively once a day, which is totally fed with 0.1 ml of the Lactobacillus paracasei each day.
- the test for the above test groups lasts for 5 weeks.
- the tooth of the mice is sliced to observe the depth caused by dental caries after the test is completed.
- the result of FIG. 3B indicates that, after the inoculation of the S. sobrinus culture solution, the aqueous sucrose solution is available without limitation for 5 weeks, so that the depth of dental caries is the most serious even to invade the part of the tooth marrow as indicated by the black arrows in FIG. 3B .
- the pathogens of periodontal disease selected in this test include Porphyromonas gingivalis, Prevotella intermedia, Centipeda periodontii , and a clinic sample of the periodontal disease bacteria obtained from the cheek tooth of a patient on periodontal disease.
- the pathogens of periodontal disease and the Lactobacillus paracasei are shaking-incubated together. After being inoculated for 0, 1, 2, 4, 6, and 12 hours, 5 ⁇ l culture solution is taken from the culture solution with 10-fold and 100-fold serial dilution, and then applied on the BBAP culture medium. They are placed in an anaerobic incubator at 37° C. for standing and incubating for 48-96 hours.
- a colony counter is used to calculate the obtained colonies. It is determined whether there is an inhibition effect of the active Lactobacillus paracasei and the sterilized Lactobacillus paracasei (dead Lactobacillus paracasei ) for the pathogens of periodontal disease.
- FIG. 4A it shows a result for inhibiting the growth of pathogens of periodontal disease with an active Lactobacillus paracasei .
- the active Lactobacillus paracasei indeed causes the phenomenon of inhibiting the growth of pathogens of periodontal disease, and when the pathogens Porphyromonas gingivalis and Centipeda periodontii are respectively combined and reacted with the active Lactobacillus paracasei for 1 hour, over 80% inhibiting ratio is achieved, and when the above two pathogens are reacted with the active Lactobacillus paracasei for 2 hours, the two pathogens (an inhibiting ratio of 100%) will be completed eliminated.
- an inhibiting ratio of about 70% is achieved, and a maximum inhibiting ratio (an inhibiting ratio of 80-90%) occurs after it is combined and reacted with the active Lactobacillus paracasei for 6 hours.
- the only tested clinic sample is the specimen of the dental plaques under the gingiva.
- the symbiosis may enhance the pathogens' resistance, and an inhibiting ratio of about 50% is achieved after being combined and reacted with the active Lactobacillus paracasei for 1 hour, and the inhibiting ratio is increased to about 70% after 2 hours, and the inhibiting ratio is changed slightly as the prolonging of the combining and reacting duration.
- FIG. 4B it shows a result for inhibiting the growth of pathogens of periodontal disease with a sterilized Lactobacillus paracasei .
- the inhibition effect of the essentially sterilized Lactobacillus paracasei for the growth of pathogens of periodontal disease is lower than that of the active Lactobacillus paracasei .
- an inhibiting ratio of 50-70% is achieved after combining and reacting the dead Lactobacillus paracasei with the pathogens of periodontal disease for 1 hour.
- an inhibiting ratio close to 80% is achieved after combining and reacting the dead Lactobacillus paracasei with the pathogens Porphyromonas gingivalis and Centipeda periodontii of periodontal disease for 4 hours.
- an inhibiting ratio close to 60% is achieved after combining and reacting the dead Lactobacillus paracasei with the Prevotella intermedia for 4 hours.
- an inhibiting ratio of less than 50% is achieved after combining and reacting the clinic sample with the Prevotella intermedia for 1 hour. The maximum inhibiting ratio occurs after the combining process has lasted for 12 hours (inhibiting ratio of about 60%).
- the high occurrence of dental caries is determined in clinic according to whether the bacteria count of the pathogen Streptococcus mutans is higher than 10 6 CFU/ml. Therefore, the special lactobacillus strain for preventing dental caries is screened by the antimicrobial cycle test of the lactobacillus cultures for the pathogens Streptococcus mutans and Streptococcus sobrinus of dental caries, which is aimed at inhibiting the growth of the Streptococcus mutans by using the lactobacilli, and thereby reducing the occurrence of dental caries. It is confirmed via a series of inhibition tests that, the Lactobacillus paracasei has the efficacy of inhibiting dental caries and pathogens of periodontal disease.
- the widely known health care function of the Lactobacillus paracasei lies in enhancing immunity and preventing allergy.
- the products containing the Lactobacillus paracasei produced according to the prevent invention such as food, oral care products or oral treatment medicine
- the products containing the Lactobacillus paracasei produced according to the prevent invention are administered or used by a user, no matter the products contain the active Lactobacillus paracasei or the dead Lactobacillus paracasei , they inhibit the pathogens of dental caries and periodontal disease in oral cavity of the user with the Lactobacillus paracasei , so as to achieve the efficacy of treating and preventing dental caries and periodontal disease.
- the functional lactobacillus—Lactobacillus paracasei suitable for human body is used for preventing the dental caries and alleviating the periodontal disease symptoms.
- the products containing the Lactobacillus paracasei are used in oral cavity for treating dental diseases, they do not cause the non-adaptation of human body, and also do not have the risk as typical noxious fluorides for curing the dental caries.
- a deposit designation of a culture of the Lactobacillus paracasei in the prevent invention is BCRC910314.
- the food containing the Lactobacillus paracasei of the prevent invention may be a liquid food, for example, drink products added with the Lactobacillus paracasei such as juice, milk, and tea.
- the food may also be a solid food such as confection, troche, biscuit, chocolate, and cheese added with the Lactobacillus paracasei .
- the food may also a gel food, such as yoghurt, jelly, pudding, and gum added with the Lactobacillus paracasei . This type of food is suitable for children to prevent dental caries.
- the product containing the Lactobacillus paracasei in the prevent invention also includes an oral hygiene product, such as toothpastes and a gargle added with the Lactobacillus paracasei , and the Lactobacillus paracasei is used to replace the typical fluoride for inhibiting the pathogens of dental disease and thereby provide a safe and effective protection for teeth.
- the product containing the Lactobacillus paracasei also includes an oral treatment medicine, such as ointments and troches added with the Lactobacillus paracasei .
- the ointments are applied on the surface of teeth or the troches are used in oral cavity in a long term, such that the time duration for the Lactobacillus paracasei to be reacted with the pathogens is prolonged; thus, the growth of the pathogens is more effectively inhibited.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Confectionery (AREA)
- Tea And Coffee (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
- Dairy Products (AREA)
Abstract
Description
- This non-provisional application claims priority under 35 U.S.C. § 119(a) on Patent Application No(s). 095129265 filed in Taiwan, R.O.C. on Aug. 9, 2006, the entire contents of which are hereby incorporated by reference.
- 1. Field of Invention
- The present invention relates to a product used in oral cavity, and more particularly, to a Lactobacillus paracasei-containing product used for inhibiting dental diseases caused by bacteria.
- 2. Related Art
- A dental caries is one of multi-factorial diseases caused by the following factors, including constituted element of teeth, configuration, position, component of saliva, pH value, secretion, viscosity, anti-bacterial factors, carbohydrate level in diet, fluoride, and microorganisms and their physical properties. Therefore, reducing the number of bacteria in oral cavity may reduce the occurrence of periodontal diseases caused by dental caries and bacteria. Generally, the bacteria affecting the health care of teeth are all in the form of a dental plaque, which is a film-shaped substance adhered on a surface of teeth in the oral cavity, with the appearance being gradually changed from a transparent appearance into a white deposit. The bacteria in the dental plaque include a variety of cocci, bacilli, and leptothrix, wherein the main bacteria of dental plaques that most easily causes dental caries or a periodontal inflammation include Streptococcus mutans, Streptococcus sanguis, Actinomyces viscosus, Streptococcus sobrinus, and Porphyromonas gingivalis.
- Currently, many researching results show that, special probiotics can reduce the occurrence of dental caries, and also decrease the number of the Streptococcus mutans of dental caries in oral cavity, which further reduces the formation of dental plaques so as to decrease a seedbed for pathogens of periodontal disease, and thereby preventing gingivitis and bone loss of an inferior alveolar bone caused by the toxin of bacteria, and reducing the occurrence of periodontal diseases. For example, a study in Japan has found that a Lactobacillus salivarius (LS1) may be used to effectively prevent dental caries. Additionally, in Helsinki University of Holland, children at the age of 1-6 who have administered milk added with lactobacilli in a long term for preventing dental caries are studied; and, young people who have administered cheeses added with a special probiotic in a short term for preventing dental caries are also studied. The result shows that the number of Streptococcus mutans in saliva is reduced by approximately 20% after 3 weeks. Furthermore, a study in Mexico also shows that continually chewing a chewing gum containing lactobacilli treated by heat sterilization once a week for 16 weeks may improve dental caries and reduce the occurrence of dental caries by approximately 42%.
- Additionally, several kinds of lactobacillus cultures for inhibiting the formation of the dental plaque are disclosed in U.S. Pat. No. 6,036,952, which include Enterococcus spp. 1357, Lactobacillus acidophilus V20, and Lactococcus lactis 1370. In addition, a product containing lactobacillus cultures of ATTC PTA-4965 and PTA-4964 is disclosed in U.S. Pat. No. 6,872,565, which is used for inhibiting dental caries caused by bacteria. The inhibition effect achieved by combining the ATTC PTA-4965 or PTA-4964 and an oral mucin or the dental plaque is used for effectively reducing the number of Streptococcus mutans. Alternatively, a method of treating and preventing dental caries, dental plaques, and periodontal diseases with lactobacillus cultures CNCM I-1984, CNCM I-1985, CNCM I-1986, CNCM I-1987, or LMG P-18997 is disclosed in U.S. Pat. No. 6,942,849, wherein the lactobacillus cultures are genetically modified to enhance the viscosity for a tooth surface film.
- Currently, it is found that, Lactobacillus paracasei may be used to promote an immunocyte to release a number of interferon, which is helpful for improving allergic diseases. Human immunocyte T lymphocytes are divided into two types according to the secreted different cytokines, wherein there is a dynamic balance between Type I and Type II T lymphocytes, and both of them are influenced by each other, thereby affecting the result of a reaction of the whole immune system to an antigen. If the reaction of Type II T lymphocyte is excessively strong, an allergic symptom occurs to a patient. The allergy may be prevented by increasing the activity of Type I T lymphocyte or inhibiting the activity of Type II T lymphocyte. When the Lactobacillus paracasei is used in human bowel, due to the difference of cell walls and cell contents, the Lactobacillus paracasei significantly promotes the activity of Type I T lymphocyte and further inhibits the effect of Type II T lymphocyte, and thus preventing allergy.
- To sum up, a variety of lactobacilli are now found to have the function of inhibiting dental caries, dental plaques, and periodontal diseases. The Lactobacillus paracasei has been used in human bowel in the past to relieve the body allergic symptom after being absorbed by the bowel. However, the efficacy that the Lactobacillus paracasei is used in oral cavity to prevent dental diseases has not been found yet.
- The prevent invention provides a Lactobacillus paracasei-containing product, which is used for inhibiting dental diseases caused by bacteria, such as dental caries, dental plaques, and periodontal diseases.
- The Lactobacillus paracasei-containing product disclosed in the prevent invention is used for inhibiting dental diseases caused by bacteria, which comprises a plurality of Lactobacillus paracasei for inhibiting the growth of bacteria of dental diseases.
- Foods, oral hygiene products or oral treatment medicine containing the Lactobacillus paracasei when being administered or applied to a user can inhibit or reduce the number of pathogens of dental caries and periodontal diseases in oral cavity of the user, thereby achieving the efficacy of preventing dental diseases, such as dental caries and periodontal diseases.
- Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
- The present invention will become more fully understood from the detailed description given herein below for illustration only, and thus is not limitative of the present invention, and wherein:
-
FIG. 1 is a DNA finger map of a Lactobacillus paracasei; -
FIGS. 2A and 2B are results of an antimicrobial cycle test for inhibiting the pathogens of dental caries with the Lactobacillus paracasei; -
FIG. 3A is a result of an animal test in a control group; -
FIG. 3B is a result of an animal test after inoculation of a pathogen S. sobrinus; -
FIG. 3C is a result of an animal test for inhibiting the pathogen with a sodium fluoride after inoculation of the pathogen S. sobrinus; -
FIG. 3D is a result of an animal test for inhibiting the pathogen with the Lactobacillus paracasei at a low bacteria count after inoculation of the pathogen S. sobrinus; -
FIG. 3E is a result of an animal test for inhibiting the pathogen with the Lactobacillus paracasei at a high bacteria count after inoculation of the pathogen S. sobrinus; -
FIG. 4A shows a result for inhibiting the growth of pathogens of periodontal disease with an active Lactobacillus paracasei; and -
FIG. 4B shows a result for; inhibiting the growth of pathogens of periodontal disease with a sterilized Lactobacillus paracasei. - To further understand the objective, structure, feature, and function of the present invention, the present invention is illustrated below in great detail through the embodiments. The above illustration about the summary of the prevent invention and the following illustration about the detailed description of the present invention are intended to demonstrate and explain the principle of the present invention, and provide further explanations for claims of the prevent invention.
- First of all, a functional lactobacillus culture for alleviating dental disease symptoms is screened from the lactobacillus cultures existed in human bowel, which is a special lactobacillus culture for preventing dental caries screened from lactobacillus cultures in a culture collection center via the antimicrobial cycle test with the main pathogens Streptococcus mutans and Streptococcus sobrinus that cause the formation of dental caries. This functional lactobacillus culture is incubated in a culture dish without oxygen at a culture temperature of 37° C. for 16-24 hours. It is found in an experimental analysis that this lactobacillus culture is a Gram-positive bacteria, a non-sporing anaerobes, and a non-mobility, which is consistent with the property of the Lactobacillus paracasei.
- To confirm whether the screened lactobacillus culture is the Lactobacillus paracasei, the assay of random amplified polymorphic DNA-polymerase chain reaction (RAPD-PCR) is carried out for the lactobacillus culture. As shown in
FIG. 1 , the RAPD-PCR technology is used to generate a DNA fingerprint S of the lactobacillus culture with an arbitrary primer. After comparison, it is found that the DNA fingerprint S does consistent with the Lactobacillus paracasei and it is different with other lactobacillus cultures. M in the figure indicates a tagged molecule of molecular weight. - Then, a nucleotide sequencing is carried out for the lactobacillus culture with PAF and 536R primers. The sequencing result is compared with a gene database (the website is www.ncbi.nlm.nih.gov), and then, it is confirmed that this lactobacillus culture is the Lactobacillus paracasei. A part of the nucleotide sequencing result of the lactobacillus culture is shown as follows:
-
AACGAGTTCTCGTTGATGATCGGTGCTTGCACCGAGATTCAACATGG AACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGG GGGATAACATTTGGAAACAGATGCTAATACCGCATAGATCCAAGAACCGC ATGGTTCTTGGCTGAAAGATGGCGTAAGCTATCGCTTTTGGATGGACCCG CGGCGTATTAGCTAGTTGGTGAGGTAATGGCTCACCAAGGCGATGATACG TAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCA AACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTC TGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTC TGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGT ATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCGNGGGTTAATT AAAA - The comparison result of the gene database is shown as follows:
- gi|55418407|gb|AY773955.1| Lactobacillus paracasei isolate 9C . . .
- gi|55418405|gb|AY773953.1| Lactobacillus paracasei isolate 3C . . .
- gi|55418404|gb|AY773952.1| Lactobacillus paracasei isolate 2C . . . .
- Finally, the carbohydrate metabolism performance of the lactobacillus culture is tested with an
API 50 CHL reagent. TheAPI 50 CHL reagent is used for identifying the difference of cultures in genus or species. It is determined by analyzing the result that, the activity of carbohydrate metabolism of the lactobacillus culture is the same as that of the Lactobacillus paracasei (not shown in data). - The screened special lactobacillus culture for preventing dental diseases is determined to be the Lactobacillus paracasei after being identified by the above analysis result.
- 1. Bacteria Test
- An antimicrobial cycle test for inhibiting the pathogen of dental caries is carried out after being modified according to the method of the National Committee for Clinical Laboratory Standards (NCCLS). A platinum loop of pathogens of dental caries is inoculated in a desired culture medium. The strain is incubated at 37° C. for 18 hours to reach a log-growth phase. The bacteria count is measured with a Smart Spec™ 3000 Spectrophtometer, and the count of pathogens of dental caries is adjusted to 1.5×108 CFU/mL. The Streptococcus mutans and Streptococcus sobrinus are uniformly applied on the desired culture medium with a thickness of 4 mm, which is stand for 15 minutes, such that the coated bacteria solution is completely adhered on the culture medium. An asepsis filter paper disc with a diameter of 6 mm is used to soak and receive the solution of the Lactobacillus paracasei. The asepsis filter paper disc is gently pressed to be completely adhered on the culture medium that is uniformly coated with the Streptococcus mutans and Streptococcus sobrinus. The size of the antimicrobial cycle is judged and read after incubation at 37° C. for 72 hours.
- Referring to
FIGS. 2A and 2B , they are results of the antimicrobial cycle test for inhibiting the pathogens of dental caries. After the Lactobacillus paracasei and the pathogens of dental caries were incubated together at 37° C. for 72 hours, the size of the antimicrobial cycle of the main pathogens Streptococcus mutans (S. mutans) and Streptococcus sobrinus (S. sobrinus) that cause dental caries is judged and read. The result of the test shows that, the antimicrobial cycle caused by the Lactobacillus paracasei for the two trains of pathogens is larger than that of a Lactobacillus rhamnosus GG, i.e., the competitive antagonize effect of the Lactobacillus paracasei for the Streptococcus mutans and Streptococcus sobrinus is more preferable than that of the Lactobacillus rhamnosus GG. The Lactobacillus rhamnosus GG is a lactobacillus culture now widely used in healthy foods for reducing the occurrence of dental caries. Therefore, using the Lactobacillus paracasei in oral cavity is helpful for reducing the number of the Streptococcus mutans, the occurrence of dental caries, and the occurrence of the periodontal diseases caused by dental caries and bacteria. - 2. Animal Test:
- Female pregnant Sprague-Dawley (SD) mice are bought from the National Laboratory Animal Center. When infant mice are 18 days old, a 0.2 ml culture solution incubated overnight for the pathogen S. sobrinus of dental caries at a log-growth phase is touched with a cotton stick, and then, the culture solution is applied in the oral cavity of female mice for inocuability. A 10% aqueous sucrose solution is available for the female mice without limitation. The step of inocuability is repeated at the second day. The caries bacteria S. sobrinus is applied in the oral cavity of the female mice with a sterile cotton stick at the third day of inocuability; and then, it is incubated in a Mitis Salivarius culture medium containing 100 μg/ml Streptomycin; finally, it is inspected whether the inocuability is successful.
- The SD infant mice are ablactated on the 20th day, and then, they are divided into groups. A 0.2 ml culture solution incubated overnight for the pathogen S. sobrinus of dental caries at a log-growth phase is touched with a cotton stick, and then, the culture solution is applied in the oral cavity of SD infant mice for inocuability. A 10% aqueous sucrose solution is available for the SD infant mice without limitation. The step of inocuability is repeated at the second day. The caries bacteria S. sobrinus is applied in the oral cavity of the SD infant mice with a sterile cotton stick at the third day of inocuability; and then, it is incubated in a Mitis Salivarius culture medium containing 100 μg/ml Streptomycin; finally, it is inspected whether the inocuability is successful.
- The aqueous sucrose solution is available for the SD infant mice without limitation during the period from the 23rd day since the mice were born to the completion of the test. Body weights are measured before the efficacy test, and the body weights are measured once a week during the test. The SD infant mice are sacrificed after 5 weeks for observing the degree of dental caries.
- Referring to
FIGS. 3A-3E , they show results of the animal test for inhibiting the pathogens of dental caries.FIG. 3A is a test result of a bank group. The pathogens of dental caries are not incubated, and the aqueous sucrose solution added with the Lactobacillus paracasei is not available throughout the test.FIG. 3B is a test result of the inoculation of a pathogen S. sobrinus.FIG. 3C is a test result for using an aqueous sucrose solution containing 0.022% NaF after inoculation of the pathogen S. sobrinus.FIG. 3D is a test result for using an aqueous sucrose solution containing 5×109 CFU/ml Lactobacillus paracasei after inoculation of the pathogen S. sobrinus.FIG. 3E is a test result for using an aqueous sucrose solution containing 5×1011 CFU/ml Lactobacillus paracasei after inoculation of the pathogen S. sobrinus. - The test conditions in
FIG. 3C include that the aqueous sucrose solution containing 0.022% NaF is available for the mice from the 23rd day after the inoculation for the pathogen S. sobrinus of dental caries is successful; the pH value of the aqueous solution is 7; the concentration of Fluoride ion is 100 ppm. The test conditions inFIGS. 3D and 3E include that the Lactobacillus paracasei at the bacteria count of 5×109 CFU/ml and 5×1011 CFU/ml are respectively fed to the mice at 23 days after the inoculation for the pathogen S. sobrinus of dental caries is successful. Each SD mouse is fed with 0.05 ml on left and right cheek respectively once a day, which is totally fed with 0.1 ml of the Lactobacillus paracasei each day. - The test for the above test groups lasts for 5 weeks. The tooth of the mice is sliced to observe the depth caused by dental caries after the test is completed. The result of
FIG. 3B indicates that, after the inoculation of the S. sobrinus culture solution, the aqueous sucrose solution is available without limitation for 5 weeks, so that the depth of dental caries is the most serious even to invade the part of the tooth marrow as indicated by the black arrows inFIG. 3B . But only low dental caries were formed, as indicated by the black arrows, when adding NaF (as shown inFIG. 3C ) or the Lactobacillus paracasei (as shown inFIGS. 3D and 3E ) to the aqueous sucrose solution, and the depth of the low dental caries is similar to that caused by dental caries in the control group (as shown inFIG. 3A ). This test shows that, the efficacies in preventing the formation of dental caries are equivalent when administering an aqueous sucrose solution containing the Lactobacillus paracasei or added with NaF. - The pathogens of periodontal disease selected in this test include Porphyromonas gingivalis, Prevotella intermedia, Centipeda periodontii, and a clinic sample of the periodontal disease bacteria obtained from the cheek tooth of a patient on periodontal disease. The pathogens of periodontal disease and the Lactobacillus paracasei are shaking-incubated together. After being inoculated for 0, 1, 2, 4, 6, and 12 hours, 5 μl culture solution is taken from the culture solution with 10-fold and 100-fold serial dilution, and then applied on the BBAP culture medium. They are placed in an anaerobic incubator at 37° C. for standing and incubating for 48-96 hours. After colonies have been formed, a colony counter is used to calculate the obtained colonies. It is determined whether there is an inhibition effect of the active Lactobacillus paracasei and the sterilized Lactobacillus paracasei (dead Lactobacillus paracasei) for the pathogens of periodontal disease.
- Referring to
FIG. 4A , it shows a result for inhibiting the growth of pathogens of periodontal disease with an active Lactobacillus paracasei. As shown in the table that, the active Lactobacillus paracasei indeed causes the phenomenon of inhibiting the growth of pathogens of periodontal disease, and when the pathogens Porphyromonas gingivalis and Centipeda periodontii are respectively combined and reacted with the active Lactobacillus paracasei for 1 hour, over 80% inhibiting ratio is achieved, and when the above two pathogens are reacted with the active Lactobacillus paracasei for 2 hours, the two pathogens (an inhibiting ratio of 100%) will be completed eliminated. As for the inhibition effect for Prevotella intermedia, when it is combined and reacted with the active Lactobacillus paracasei for 1 hour, an inhibiting ratio of about 70% is achieved, and a maximum inhibiting ratio (an inhibiting ratio of 80-90%) occurs after it is combined and reacted with the active Lactobacillus paracasei for 6 hours. The only tested clinic sample is the specimen of the dental plaques under the gingiva. Since the clinic sample is a combined flora, the symbiosis may enhance the pathogens' resistance, and an inhibiting ratio of about 50% is achieved after being combined and reacted with the active Lactobacillus paracasei for 1 hour, and the inhibiting ratio is increased to about 70% after 2 hours, and the inhibiting ratio is changed slightly as the prolonging of the combining and reacting duration. - Referring to
FIG. 4B , it shows a result for inhibiting the growth of pathogens of periodontal disease with a sterilized Lactobacillus paracasei. The inhibition effect of the essentially sterilized Lactobacillus paracasei for the growth of pathogens of periodontal disease is lower than that of the active Lactobacillus paracasei. As for the pathogens of periodontal disease, an inhibiting ratio of 50-70% is achieved after combining and reacting the dead Lactobacillus paracasei with the pathogens of periodontal disease for 1 hour. As for the pathogens Porphyromonas gingivalis and Centipeda periodontii of periodontal disease, an inhibiting ratio close to 80% is achieved after combining and reacting the dead Lactobacillus paracasei with the pathogens Porphyromonas gingivalis and Centipeda periodontii of periodontal disease for 4 hours. As for the Prevotella intermedia, an inhibiting ratio close to 60% is achieved after combining and reacting the dead Lactobacillus paracasei with the Prevotella intermedia for 4 hours. As for the clinic sample, an inhibiting ratio of less than 50% is achieved after combining and reacting the clinic sample with the Prevotella intermedia for 1 hour. The maximum inhibiting ratio occurs after the combining process has lasted for 12 hours (inhibiting ratio of about 60%). - The result of this test shows that, although the inhibition effect of the sterilized Lactobacillus paracasei for pathogens of periodontal disease is weaker than that of the active Lactobacillus paracasei, the sterilized Lactobacillus paracasei still has the inhibition effect.
- The high occurrence of dental caries is determined in clinic according to whether the bacteria count of the pathogen Streptococcus mutans is higher than 106 CFU/ml. Therefore, the special lactobacillus strain for preventing dental caries is screened by the antimicrobial cycle test of the lactobacillus cultures for the pathogens Streptococcus mutans and Streptococcus sobrinus of dental caries, which is aimed at inhibiting the growth of the Streptococcus mutans by using the lactobacilli, and thereby reducing the occurrence of dental caries. It is confirmed via a series of inhibition tests that, the Lactobacillus paracasei has the efficacy of inhibiting dental caries and pathogens of periodontal disease.
- The widely known health care function of the Lactobacillus paracasei lies in enhancing immunity and preventing allergy. However, when the products containing the Lactobacillus paracasei produced according to the prevent invention, such as food, oral care products or oral treatment medicine, are administered or used by a user, no matter the products contain the active Lactobacillus paracasei or the dead Lactobacillus paracasei, they inhibit the pathogens of dental caries and periodontal disease in oral cavity of the user with the Lactobacillus paracasei, so as to achieve the efficacy of treating and preventing dental caries and periodontal disease. The functional lactobacillus—Lactobacillus paracasei suitable for human body is used for preventing the dental caries and alleviating the periodontal disease symptoms. When the products containing the Lactobacillus paracasei are used in oral cavity for treating dental diseases, they do not cause the non-adaptation of human body, and also do not have the risk as typical noxious fluorides for curing the dental caries.
- A deposit designation of a culture of the Lactobacillus paracasei in the prevent invention is BCRC910314. The food containing the Lactobacillus paracasei of the prevent invention may be a liquid food, for example, drink products added with the Lactobacillus paracasei such as juice, milk, and tea. The food may also be a solid food such as confection, troche, biscuit, chocolate, and cheese added with the Lactobacillus paracasei. In addition, the food may also a gel food, such as yoghurt, jelly, pudding, and gum added with the Lactobacillus paracasei. This type of food is suitable for children to prevent dental caries. The product containing the Lactobacillus paracasei in the prevent invention also includes an oral hygiene product, such as toothpastes and a gargle added with the Lactobacillus paracasei, and the Lactobacillus paracasei is used to replace the typical fluoride for inhibiting the pathogens of dental disease and thereby provide a safe and effective protection for teeth. In addition, the product containing the Lactobacillus paracasei also includes an oral treatment medicine, such as ointments and troches added with the Lactobacillus paracasei. The ointments are applied on the surface of teeth or the troches are used in oral cavity in a long term, such that the time duration for the Lactobacillus paracasei to be reacted with the pathogens is prolonged; thus, the growth of the pathogens is more effectively inhibited.
- The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW095129265 | 2006-08-09 | ||
TW095129265A TW200808191A (en) | 2006-08-09 | 2006-08-09 | Product containing Lactobacillus paracasei |
TW95129265A | 2006-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080118444A1 true US20080118444A1 (en) | 2008-05-22 |
US7666407B2 US7666407B2 (en) | 2010-02-23 |
Family
ID=39173290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/637,711 Active 2027-11-12 US7666407B2 (en) | 2006-08-09 | 2006-12-13 | Lactobacillus paracasei-containing product |
Country Status (3)
Country | Link |
---|---|
US (1) | US7666407B2 (en) |
JP (1) | JP4705063B2 (en) |
TW (1) | TW200808191A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100047190A1 (en) * | 2006-12-19 | 2010-02-25 | Basf Se | Uses and methods for preventing and/or treating caries caused by mutants streptococci |
WO2012100991A1 (en) * | 2011-01-24 | 2012-08-02 | Basf Se | Oral health improving compositions |
GB2548930A (en) * | 2016-04-01 | 2017-10-04 | Genmont Biotech Inc | Use of a heat-inactivated lactobacillus strain and composition for inhibiting bacterial adhesion of oral pathogens |
US10143712B2 (en) | 2009-07-16 | 2018-12-04 | Hiroshima University | Prophylactic, ameliorating or therapeutic agent for oral diseases |
CN110772474A (en) * | 2019-12-10 | 2020-02-11 | 广州瑞誉化工科技有限公司 | Probiotic oral spray |
CN111454862A (en) * | 2020-04-12 | 2020-07-28 | 生合生物科技(扬州)有限公司 | Lactobacillus paracasei freeze-dried powder with oral health function, preparation method and application |
US11771644B1 (en) * | 2022-07-06 | 2023-10-03 | Zhejiang Airsun Commodity Co., Ltd. | Whitening toothpaste capable of effectively removing dental plaque and tartar |
WO2024009148A1 (en) * | 2022-07-04 | 2024-01-11 | Tayebi Sepideh | Chocolate formulation enriched with lactobacillus paracasei, l-tryptophan, and l-theanine for stress relief |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5108068B2 (en) * | 2010-08-30 | 2012-12-26 | 生展生物科技股▲分▼有限公司 | Lactobacillus fermentum SG-A95 (Lactobacillus fermentum SG-A95) for improving bacteria in the oral cavity and health composition thereof |
EP2729559B1 (en) * | 2011-07-06 | 2018-08-22 | DuPont Nutrition Biosciences ApS | Method for reducing the viscosity of a microorganism-containing suspension or concentrate |
TWI398259B (en) * | 2011-10-14 | 2013-06-11 | Genmont Biotech Inc | Composition and use of lactobacillus paracasei strain gmnl-133 in treating atopic dermatitis or other allergic diseases |
JP6351985B2 (en) * | 2013-01-30 | 2018-07-04 | 株式会社 ソーシン | Oral composition |
US20180014546A1 (en) * | 2013-10-04 | 2018-01-18 | Elizabeth J. Summer | Broad Spectrum Bacteriocin for Control of Unwanted Bacteria |
CN104651245B (en) * | 2013-11-15 | 2017-10-13 | 景岳生物科技股份有限公司 | Probiotic composition and use thereof for treating picornavirus infection |
GB2520483B (en) * | 2013-11-15 | 2017-06-07 | Genmont Biotech Inc | A probiotic composition for treating picornavirus infection and its use thereof |
US20210401914A1 (en) * | 2019-07-04 | 2021-12-30 | Sosin Co., Ltd. | Oral composition for animal and periodontal disease preventive, infection disease preventive, and mouth odor preventive using the oral composition |
KR102217525B1 (en) * | 2020-08-18 | 2021-02-19 | 주식회사 메디오젠 | Probiotics for prevention or treatment of periodontitis and use thereof |
KR102217518B1 (en) * | 2020-08-18 | 2021-02-19 | 주식회사 메디오젠 | Probiotics for prevention or treatment of periodontitis and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7375080B1 (en) * | 1999-05-28 | 2008-05-20 | Naidu A Satyanarayan | Immobilized lactoferrin (Im-LF) antimicrobial agents and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990024297A (en) | 1997-08-07 | 1999-04-06 | 오종석 | Novel Lactic Acid Bacteria Inhibit Plaque Formation in Human Oral cavity |
IL140641A (en) | 1998-08-12 | 2007-07-04 | Nestle Sa | Incorporation of exogenous lactic bacteria into the oral microflora |
US6872565B2 (en) | 2003-01-29 | 2005-03-29 | Biogaia Ab | Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries |
EP1634948A1 (en) * | 2004-09-10 | 2006-03-15 | Basf Aktiengesellschaft | Means and methods for preventing and/or treating caries |
WO2006048457A1 (en) | 2004-11-05 | 2006-05-11 | Dsm Ip Assets B.V. | Probiotica and polyphenol |
EP1858340B1 (en) | 2005-02-15 | 2010-07-14 | Barry R. Goldin | A food containing a probiotic and an isolated beta-glucan and methods of use thereof |
-
2006
- 2006-08-09 TW TW095129265A patent/TW200808191A/en unknown
- 2006-12-13 US US11/637,711 patent/US7666407B2/en active Active
-
2007
- 2007-03-07 JP JP2007057509A patent/JP4705063B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7375080B1 (en) * | 1999-05-28 | 2008-05-20 | Naidu A Satyanarayan | Immobilized lactoferrin (Im-LF) antimicrobial agents and uses thereof |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100047190A1 (en) * | 2006-12-19 | 2010-02-25 | Basf Se | Uses and methods for preventing and/or treating caries caused by mutants streptococci |
US10143712B2 (en) | 2009-07-16 | 2018-12-04 | Hiroshima University | Prophylactic, ameliorating or therapeutic agent for oral diseases |
WO2012100991A1 (en) * | 2011-01-24 | 2012-08-02 | Basf Se | Oral health improving compositions |
EP3424516A1 (en) * | 2011-01-24 | 2019-01-09 | Basf Se | Oral health improving compositions |
US10835485B2 (en) | 2011-01-24 | 2020-11-17 | Basf Se | Oral health improving compositions |
GB2548930A (en) * | 2016-04-01 | 2017-10-04 | Genmont Biotech Inc | Use of a heat-inactivated lactobacillus strain and composition for inhibiting bacterial adhesion of oral pathogens |
US10300094B2 (en) | 2016-04-01 | 2019-05-28 | Genmont Biotech Inc. | Method and composition for inhibiting bacterial adhesion of oral pathogens |
GB2548930B (en) * | 2016-04-01 | 2020-04-22 | Genmont Biotech Inc | Heat-inactivated Lactobacillus rhamnosis GMNL-464 for use in the prevention of halitosis |
CN110772474A (en) * | 2019-12-10 | 2020-02-11 | 广州瑞誉化工科技有限公司 | Probiotic oral spray |
CN111454862A (en) * | 2020-04-12 | 2020-07-28 | 生合生物科技(扬州)有限公司 | Lactobacillus paracasei freeze-dried powder with oral health function, preparation method and application |
WO2024009148A1 (en) * | 2022-07-04 | 2024-01-11 | Tayebi Sepideh | Chocolate formulation enriched with lactobacillus paracasei, l-tryptophan, and l-theanine for stress relief |
US11771644B1 (en) * | 2022-07-06 | 2023-10-03 | Zhejiang Airsun Commodity Co., Ltd. | Whitening toothpaste capable of effectively removing dental plaque and tartar |
Also Published As
Publication number | Publication date |
---|---|
JP4705063B2 (en) | 2011-06-22 |
JP2008037859A (en) | 2008-02-21 |
TW200808191A (en) | 2008-02-16 |
US7666407B2 (en) | 2010-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7666407B2 (en) | Lactobacillus paracasei-containing product | |
EP1955702B1 (en) | Lactobacillus paracasei-containing product for use in inhibiting dental diseases | |
US11871775B2 (en) | Method of inhibiting oral pathogens | |
Meurman et al. | Probiotics: evidence of oral health implications | |
KR101900992B1 (en) | Prophylactic or therapeutic agent for oral diseases | |
JP4486957B2 (en) | Use of lactic acid bacteria to reduce caries and bacteria that cause caries | |
US11274275B2 (en) | Lactobacillus paracasei ET-22 and use thereof | |
Pandey et al. | Probiotics: Healthy bugs and nourishing elements of diet | |
Widyarman et al. | Lactobacillus reuteri containing probiotic lozenges consumption reduces Streptococcus mutans, Streptococcus sobrinus, Porphyromonas gingivalis, and Aggregatibacter actinomycetemcomitans in orthodontic patients | |
Deogade | Probiotics: contributions to oral and dental health | |
JP2006508943A (en) | Methods for inhibiting yeast growth | |
Chan et al. | Can infants catch caries? A review of the current evidence on the infectious nature of dental caries in infants | |
CN112616932A (en) | Goat milk tablet for protecting oral health and preparation method thereof | |
CN107530382A (en) | Caries preventive agent and preventing decayed tooth composition | |
Almståhl et al. | Acid-producing capacity from sugars and sugar alcohols among Lactobacillus isolates collected in connection with radiation therapy | |
Nadelman et al. | The effect of probiotics on oral health | |
Amalia | Milk Lactoperoxidase System and Lactoperoxidase Enzyme on the Potential of Streptococcus Mutans in Children’s Saliva | |
Abbas | Oral microbiota and it's role in dental caries | |
Gomes et al. | Action of probiotics on oral pathogens: Efficacy and controversies | |
McBain et al. | An introduction to probiotics for dental health | |
Janczarek | Probiotics–a final countdown for caries | |
Malavalli | Assessment of the Effect of Probiotic Yogurt Consumption on Salivary pH, Buffering Capacity and Salivary Calcium Level in 6-12 Year Old Children-An in vivo Study | |
Alaki et al. | Evaluation of Inhibitory Effect of Different Probiotic Strains on Salivary Mutans Streptococci Count in Experimental Rats-Randomized Control Animal Study | |
ARABIA | The Effect of Probiotic product on Salivary Cariogenic Bacterial Counts Among a Group of Preschool Children in Jeddah, Saudi Arabia: A Randomized Clinical Trial. | |
Morad et al. | Evaluation of the Effect of Dairy Products on Streptococci and Lactobacilli in Saliva on Group of Egyptian Children |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENMONT BIOTECH INC., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HSU, CHING-HSIANG;CHEN, YA-HUI;WANG, YING-YU;AND OTHERS;REEL/FRAME:018675/0352;SIGNING DATES FROM 20061106 TO 20061110 Owner name: GENMONT BIOTECH INC.,TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HSU, CHING-HSIANG;CHEN, YA-HUI;WANG, YING-YU;AND OTHERS;SIGNING DATES FROM 20061106 TO 20061110;REEL/FRAME:018675/0352 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |